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ABSTRACT
With an increasing prevalence during the past decades, atopic dermatitis has become a global health issue. A literature search following 
a targeted approach was undertaken to perform this non-systematic review, which intends to provide an overview of the epidemiology, 
pathophysiology, clinical features, comorbidities, and current therapies for the treatment of atopic dermatitis. In sum, this is a hetero-
geneous skin disorder associated with variable morphology, distribution, and disease course. Although not completely understood, its 
pathogenesis is complex and seems to result from a combination of genetic and environmental factors that induce skin barrier dys-
function, cutaneous and systemic immune dysregulation, skin microbiota dysbiosis, and a strong genetic influence. Diagnosis is based 
on specific criteria that consider patient and family history and clinical manifestations. Overall disease severity must be determined by 
evaluating both objective signs and subjective symptoms. Therapeutic goals require a multistep approach, focusing on reducing pruri-
tus and establishing disease control. Patients should be advised on basic skin care and avoidance of triggers. Topical anti-inflammatory 
agents should be considered in disease flares or chronic/recurrent lesions. In case of inadequate response, phototherapy, systemic 
immunosuppressants and, more recently, dupilumab, should be added. Nevertheless, the treatment of moderate-to-severe atopic 
dermatitis remains challenging and novel, efficacious, safe and targeted treatments are urgently needed. In conclusion, although the 
last few years have seen important improvement in the understanding of the disease, future research in atopic dermatitis will continue 
exploring gene-environment interactions and how it affects pathophysiology, disease severity, and treatment outcomes.
Keywords: Dermatitis, Atopic/complications; Dermatitis, Atopic/diagnosis; Dermatitis, Atopic/epidemiology; Dermatitis, Atopic/etiology; 
Dermatitis, Atopic/prevention and control;Dermatitis, Atopic/therapy
RESUMO
Com uma prevalência crescente nas últimas décadas, a dermatite atópica tornou-se um problema de saúde global. Foi realizada uma 
revisão não sistemática com base numa pesquisa bibliográfica direcionada à epidemiologia, fisiopatologia, características clínicas, 
comorbilidades e tratamento da dermatite atópica. Em resumo, a dermatite atópica é uma patologia cutânea heterogénea associada 
a morfologia, distribuição e curso da doença variáveis. A sua patogénese é complexa, combinando fatores genéticos e ambientais 
que condicionam a disfunção da barreira epidérmica, a desregulação imune cutânea e sistémica e a disbiose do microbioma da pele. 
O diagnóstico baseia-se em critérios clínicos específicos, incluindo história pessoal e familiar de atopia, evolução da doença e mani-
festações clínicas. A gravidade da doença é determinada através da avaliação dos sinais objetivos e dos sintomas subjetivos. A sua 
abordagem deve ser progressiva, focada na redução do prurido e no controlo da doença. Os doentes devem ser aconselhados sobre 
os cuidados básicos a ter e evicção de agressores externos. Em situações de agudização ou lesões crónico-recidivantes, devem ser 
aplicados anti-inflamatórios tópicos. Na ausência de resposta ou controlo adequado no médio prazo, deve ponderar-se fototerapia, 
imunossupressores sistémicos ou, mais recentemente, dupilumab. Contudo, o tratamento da dermatite atópica moderada a grave 
permanece desafiador, sendo urgente o desenvolvimento de novas terapêuticas, eficazes, seguras e direcionadas. Concluindo, ape-
sar de atualmente haver uma melhor compreensão e um maior conhecimento da doença, as investigações futuras deverão continuar 
a explorar a interação entre fatores genéticos e ambientais e seus efeitos na fisiopatologia e gravidade da doença, bem como nos 
resultados do tratamento.
Palavras-chave: Dermatite Atópica/complicações; Dermatite Atópica/diagnóstico; Dermatite Atópica/epidemiologia; Dermatite Atópi-
ca/etiologia; Dermatite Atópica/prevenção e controlo; Dermatite Atópica/tratamento
INTRODUCTION 
Atopic dermatitis (AD), also known as atopic eczema, 
is a common, chronic and relapsing inflammatory skin dis-
ease with an increasing incidence during the past few dec-
ades, especially in developed countries.1–4 AD has become 
a global health issue as it causes high health-care costs 
worldwide and is associated with considerable morbid-
ity and quality of life (QoL) impairment, disease burden 
comparable to other chronic conditions like epilepsy, dia-
betes mellitus and cystic fibrosis.1,2,5–8 AD often develops 
during childhood, and has a wide spectrum of symptoms 
and signs which contribute towards profound functional dis-
turbances, limits the ability to perform daily life activities and 
causes psychosocial distress and stigma.2,9 The psychoso-
cial and financial implications of AD affect patients, their 
families, health care providers, and society in general.1,5,8
A
R
TI
G
O
 D
E 
R
EV
IS
Ã
O
Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com607
Torres T, et al. Update on atopic dermatitis, Acta Med Port 2019 Sep;32(9):606–613
The pathophysiological concepts underlying AD have 
shifted towards an integrated view, in which genetic and 
environmental factors interact contributing to varying 
degrees of epidermal barrier disruption, activation of differ-
ent T cell subsets, and commensal skin microbiota dysbio-
sis, causing the varying clinical presentations, presumably 
encompassing a variety of subtypes with distinct and over-
lapping pathological mechanisms.2 Although the underlying 
mechanisms causing these conditions are largely unknown 
and the absolute magnitude of the risks has not yet been 
well defined, AD has been considered more recently as a 
systemic disorder associated with increased risk of various 
allergic and non-allergic comorbidities, namely food aller-
gies, respiratory disorders, cutaneous and extra-cutaneous 
infections, neuropsychiatric conditions, other inflammatory 
and autoimmune diseases, lymphoma, and cardiovascular 
disease, with important implications for management and 
treatment.1,2,5,6,9–13
Therapeutic goals require a multistep approach, focused 
on reducing pruritus and establishing disease control. 
Treatment selection is based primarily on disease severi-
ty but also on the patient’s age, comorbidities, compliance, 
and costs.2 Licensed treatment options for moderate-to-se-
vere AD are limited, but current insights from basic and clin-
ical research are now being translated into clinical trials and 
approval of new treatments.1,2,14,15
A literature search following a targeted approach was 
undertaken to perform this non-systematic review, which 
aims to provide an overview of the epidemiology, patho-
physiology, clinical features, associated comorbid health 
disorders, as well as the current and novel therapies for the 
treatment of AD.
Epidemiology
According to the WHO Global Burden of Diseases initia-
tive’s data, it is estimated that AD affects at least 230 million 
people worldwide, being the leading cause of the non-fa-
tal disease burden within skin conditions.2,16 AD is one of 
the most common chronic diseases worldwide and the 
most common inflammatory skin disorder in the developed 
world, affecting men and women of all races, children and 
adults, often occurring in families with other atopic diseases 
(bronchial asthma and/or allergic rhinitis).2,14,17,18 Originally 
regarded as an early childhood disease, with an estimated 
prevalence of 15% – 25% in children, more recent evidence 
shows that AD is also very prevalent in adults, with rates 
ranging from 1% to 10%.2,6,14,17,19–27 Even though epidemio-
logic studies report different prevalence estimates through-
out the world, even between highly genetically similar popu-
lations, the overall prevalence of AD has increased by 2- to 
3-fold during the past decades in industrialized countries, 
especially in the United States (US), Europe, and Japan, 
with a maximum prevalence of nearly 30% in some popu-
lations.4,18,23,25,26 The causes of this increase are unknown, 
although several systematic large-scale studies point to 
numerous genetic, social and/or environmental factors as 
potential contributors.2,18,23,24,28
Although AD can manifest at any age in life, the inci-
dence peaks in infancy with approximately 45% of all cases 
beginning within the first six months of life, 60% during the 
first year, and 80% – 90% before the fifth year of life.1,2,6,18,25 
AD is often the first step in the development of other atopic 
diseases, such as allergic rhinitis, asthma and food aller-
gy, the so-called ‘atopic march’, characterized by a typical 
sequence of atopic diseases preceding the development 
of other allergic disorders later in life.4,14,23,25 The number 
of patients who will develop asthma and/or allergic rhinitis 
depends on the underlying features of their condition,23,24 
with evidence suggesting that 50% of those who develop AD 
before the age of 2 will develop asthma during subsequent 
years. Furthermore, AD children who develop asthma and 
allergic rhinitis are more likely to have severe disease.23,25
The course of AD can be continuous for many years but 
can also show a relapsing-remitting pattern.2 Early studies 
had suggested that the disease clears in > 50% of affect-
ed children, with just the more severe cases persisting 
into adulthood.23 But more recent cross-sectional stud-
ies showed that the proportion of patients with persistent 
or adult-onset disease or with relapses after long asymp-
tomatic intervals is much higher than previously thought.2 
One in four adults with AD report adult-onset disease, which 
appears to be associated with a different disease pheno-
type compared with childhood-onset AD.29
According to an international, cross-sectional, web-
based survey performed in the US, Canada, France, 
Germany, Italy, Spain, United Kingdom, and Japan, region-
al variability of adult AD prevalence was observed within 
countries. Among participants by region, the point preva-
lence of adult AD in the overall populations was 4.9% in the 
US, 4.4% in the EU, 3.5% in Canada, and 2.1% in Japan. 
Severity varied by scale and region. However, the propor-
tion of subjects reporting severe disease was lower than in 
mild or moderate disease.22
The first published data regarding AD estimates in the 
Portuguese population revealed that from approximately 78 
300 adult AD patients (0.7% – 1.6% of the Portuguese adult 
population) seen by a dermatologist in 2017, 40% – 45% 
had moderate or severe disease,21 confirming that severe 
AD represents a small proportion of the overall AD popula-
tion regardless of measure or region.22 Most surveyed phy-
sicians reported an increase in the number of their patients 
over the last 3 years; most patients were young adults, 48% 
under 35 years old,21 which also corroborates the interna-
tional trends. Out of 22 354 Portuguese children under 16, 
attending dermatology consultation, 3214 (14.4%) had AD.30
Etiology and pathophysiology
The global increasing AD prevalence cannot be attribut-
ed to genetics alone as its aetiology is multifactorial involv-
ing the interaction between genetics, immune and environ-
mental factors.23,31 Environmental exposures may trigger 
and/or flare disease in predisposed individuals. Exposure 
to personal care or professional cleansing products, cli-
mate, pollution, food and other exogenous factors act in 
A
R
TIG
O
 D
E R
EVISÃ
O
Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com608
Torres T, et al. Update on atopic dermatitis, Acta Med Port 2019 Sep;32(9):606–613
concert with genetic and acquired skin barrier disruption 
and immune imbalance to influence disease manifesta-
tions.23,31 Understanding these complex interacting factors 
is crucial to develop targeted interventions to prevent or 
mitigate disease. Moreover, patients require counselling on 
optimal regimens for avoiding irritants and pruritogens and 
other harmful exposures.31
The strongest known risk factor for AD is a family his-
tory of atopic diseases, particularly AD.2,23,27 The presence 
of an atopic disease in one parent is estimated to increase 
1.5-fold a child’s risk of developing AD, whereas the risk 
is increased ~3-fold and ~5-fold, respectively, if one or 
both parents have AD. Other risk factors associated with 
increased prevalence include living in an urban setting and 
in regions with low ultraviolet light exposure or dry climat-
ic conditions, diets rich in sugars and polyunsaturated fat-
ty acids (typical of Western countries), repeated exposure 
to antibiotics before five years of age, smaller family size, 
higher socioeconomic status and higher level of family 
education.2,23,24
Effects of maternal and/or postnatal exposure to stress, 
tobacco, antibiotics or alcohol consumption; long-term 
exclusive breastfeeding; routine childhood vaccinations; 
viral or bacterial infections; air pollutants, farm environments 
and household hair-bearing pets, all remain inconsistent as 
risk factors for AD.2,27,31 In contrast, some maternal expo-
sures may actually lower the risk of AD in childhood, includ-
ing dietary and probiotics’ exposures.23,31
The pathogenesis of AD is complex and combines skin 
barrier dysfunction, cutaneous and systemic immune dys-
regulation, the dysbiosis of the skin bacterial microbiome, 
and genetic factors.2,7,11,25 Skin barrier abnormalities appear 
to be associated with mutations or impaired expression 
of the filaggrin gene, which encodes a structural protein 
essential for skin barrier formation.2,14,23 Moreover, dys-
regulation of lipid metabolism with reduction of ceramides 
are important factors,25 leading to trans-epidermal water 
loss and increased penetration of irritants, allergens and 
microbes into the skin.7,14,23 Barrier disruption leads to 
chronic inflammation with epidermal hyperplasia and cel-
lular infiltrates, including dendritic cells, eosinophils, and 
T-cells.7,11 AD is currently considered a biphasic or com-
bined T cell-mediated disease concerning immune dysreg-
ulation.23 A type-2 T-helper cell (Th2) signal rich in IL-4, IL-5, 
IL-13, IL-25, and IL-31 predominates in the acute phase, 
whereas a Th2–Th1 switch promotes disease chronicity.23 
Furthermore, IL-22-secreting Th22 cells, and in a smaller 
degree, IL-17-secreting Th17 cells play a role in the initia-
tion and maintenance of AD.11 
The innate immune system provides the first line of 
defence against microbial pathogens. Defective innate 
immune responses, with a reduction of antimicrobial pep-
tides, contribute to increased bacterial and viral infec-
tions.14,23 This interplay of factors leads to T cell responses 
in the skin with resultant release of chemokines and pro-in-
flammatory cytokines (namely TSLP and IL-4) that promote 
immunoglobulin E (IgE) production, skin and systemic 
inflammation and high IL-31 leading to severe pruritus.25 
Still, although IgE has been considered a hallmark of atopic 
diseases, including AD, IgE itself is not a key mediator of 
AD pathogenesis.11 Finally, the skin of patients with AD has 
substantial microbiotal abnormalities; whether these chang-
es are primary or secondary to epidermal barrier disruption 
and Th2 cell-skewed immunity is still uncertain. Microbiota 
diversity decreases in inflamed AD skin in favour of mem-
bers of the genus Staphylococcus. S. aureus in particular, 
colonizes approximately 90% of AD patients25 and express-
es numerous virulence factors that have proven roles in the 
pathogenesis of both superficial and invasive infections, 
contributing to AD pathogenesis or disease exacerbation 
through mechanisms acting on keratinocytes and immune 
cells.2,7 During treatment and recovery, the microbiota com-
position reverts to the pre-flare composition.7,32 In addition 
to the well-characterized role of S. aureus in AD, other 
organisms have substantial roles, including yeasts, as for 
example, Malassezia spp., which can directly stimulate skin 
inflammation.2
The relative and temporal influences of all these mech-
anisms could explain the clinical heterogeneity observed 
among patients with AD.2 
Clinical features and diagnostic
AD is a lifelong disease with highly variable clinical 
phenotypes, partly related to age, ethnicity and disease 
severity.2,7,29,33,34 AD is characterized by acute flare-ups 
of eczematous, oozing or weeping pruritic lesions over 
dry skin. Chronic lesions include red or brownish patch-
es of dry, cracked or scaly skin with lichenification and 
prurigo nodules. Itchy skin, especially at night, results in 
sleep disturbance and fatigue, as well as mental health 
symptoms.2,7,9,18,23,29 
There is no specific diagnostic test or pathognomonic 
laboratory biomarker for AD diagnosis, which is established 
by characteristic clinical features, pruritus, disease evolu-
tion and a personal and/or family history of atopy.6,14,25 The 
most typical feature, the elevation of total or allergen-spe-
cific IgE levels in serum, is not present in all individuals, 
presumably distinguishing two forms of the disease, the 
non-IgE-associated (‘intrinsic’) AD and the IgE-associated 
(‘extrinsic’) AD.6,14,18 
Clinical diagnosis is usually easy except in infants, tod-
dlers and in elderly people, which present more-atypical 
clinical features. Skin biopsies can help to exclude other 
common diseases mimicking, coexisting or complicating 
AD, malignant diseases such as cutaneous T-cell lympho-
ma or, remarkably in childhood, other rare diseases such 
as primary immunodeficiencies and nutritional deficien-
cies. To support diagnosis, several sets of criteria have 
been proposed over time, but the original Hanifin and 
Rajka criteria35 remain the most widely used worldwide.14 
The Hanifin and Rajka criteria and the American Academy 
of Dermatology Consensus Criteria both distinguish the 
so-called essential, common and associated features of AD 
and can be useful in the clinical setting.2,33,35–37 Accordingly, 
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the essential features are intense itch; acute, subacute or 
chronic eczematous lesions; and a chronic or relapsing 
disease course. AD lesions can occur on any body part, 
although typically showing an age-related distribution pat-
tern. Infants often show widely distributed and more-acute 
skin lesions characterized by severe erythema, oedema, 
excoriations and serous exudate manifesting as oozing 
and crusting, characteristically located on the face/ cheeks 
and trunk, with sparing of the diaper area. In childhood, AD 
becomes more localized and chronic with paler erythema, 
xerosis and skin thickened from repetitive scratching com-
monly affecting flexor surfaces. Adolescents and adults can 
have a diffuse pattern of AD but also localized lesions, most 
typically affecting hands, eyelids and flexures. Adults can 
present only with chronic hand AD or the head-and-neck 
subtype of AD, which involves the upper trunk, shoulders 
and scalp.2,18,23,25,29
Other features that are commonly observed but that are 
not a prerequisite to establish diagnosis, include early onset 
(typically during the first year of life), a personal and/or fam-
ily history of atopic diseases, specific IgE reactivity and 
the presence of generalized skin dryness.2,7 Morphological 
subtypes of AD include the follicular type, which is char-
acterized by densely aggregated follicular papules and is 
frequent in dark-skinned individuals and people of Asian ori-
gin;25 and the chronic prurigo type, which is characterized 
by erythematous, often excoriated papules and indurated 
nodules and is sometimes seen in patients with long-stand-
ing disease.2
Disease severity and quality of life
Clinical measures are the basis to define the severity of 
AD and to assess therapy outcomes. The overall disease 
severity must be determined by evaluating both objective 
signs (physician assessments of disease severity) and 
subjective symptoms (patient-reported symptoms and QoL 
outcomes). The most commonly used tools for assess-
ing AD severity include Eczema Area and Severity Index 
(EASI); SCORing Atopic Dermatitis (SCORAD); Physician 
Global Assessment (PGA); body surface area (BSA); Atopic 
Dermatitis Severity Index (ADSI); Six Area, Six Sign Atopic 
Dermatitis (SASSAD); Patient Oriented Eczema Measure 
(POEM); Dermatology Life Quality Index (DLQI); and pruri-
tus Numerical Rating Scale (NRS).2,6,14,38–41
SCORAD and EASI measure AD signs and the extent 
of the area affected.2 SCORAD attributes around 60% of 
the total score to the intensity of lesions, 20% to spread 
and 20% to subjective signs scored by the patient.2 A 
SCORAD > 50 is regarded as severe, while SCORAD 
scores < 25 are considered mild.14 The patient-oriented 
SCORAD (PO-SCORAD) is a physician-independent tool 
for assessing AD severity.14 In contrast, EASI is a signs-only 
score that assesses visible lesions only, giving the same 
weight to both intensity and extent of the lesions, without 
evaluating AD subjective symptoms.2,14 POEM is a symp-
toms-only score to measure the subjective symptoms 
in clinical trials, but not the objective signs.14 POEM and 
PO-SCORAD are the preferred instruments to measure 
patient-reported symptoms in AD trials.2,42 The Investigators 
Global Assessment (IGA), based on an investigator-only 
single assessment, is also a frequently used tool.14 Since 
both objective and subjective assessments of disease 
severity are important, clinical characteristics such as dis-
ease recurrence or persistence and location of affected are-
as should be reflected in the overall judgement of disease 
severity and consideration of therapy choice.18,41
DLQI and the Infants’ Dermatology Quality of Life Index 
(IDQOL) are the QoL instruments most commonly used in 
AD, taking into account the different disease domains, in 
particular signs and symptoms; sleep quality; work perfor-
mance and social and emotional well-being; to quantify the 
different aspects of the individual burden of AD in a real-
world setting.43–45 
However, no well-validated instrument that can quan-
tify the physical, social, emotional, cognitive, work-related 
and disease-related symptoms, as well as the AD economic 
impact, and perform well in both sexes and across all ages 
and ethnic groups, has been identified, turning the devel-
opment and validation of new health-related quality of life 
(HRQoL) instruments a preeminent need.46 There is a simi-
lar need to delineate clear, practical definitions and severity 
measures for AD in the clinical setting.6
In general, most AD cases can be regarded as mild, 
both in children and adults, but 10% – 18% suffer from 
severe AD. While 67% of children with AD present with mild 
disease and the remaining present with moderate-to-severe 
AD,2 the percentage of severe cases seems to be higher in 
the adult AD population.14
Comorbidities
Patients with AD are at a slightly, but significantly, 
increased risk of all-cause mortality compared to the gen-
eral population.5 The relation between AD and food allergy, 
asthma, and allergic rhinitis as part of the ‘atopic march’ has 
been extensively documented. AD is also associated with 
an increased risk of irritant and allergic contact dermatitis, 
and hand dermatitis.2,4,5,12,18
Remarkably in children, sleep disturbances may be 
related with growth impairment, lower school performance, 
attention deficit hyperactivity disorders, and higher accident 
risks.9
Potentially under-recognized AD non-allergic comor-
bidities include cutaneous and extra-cutaneous infections, 
other autoimmune- or immune-mediated diseases, neu-
ropsychiatric conditions, and emerging comorbidities, such 
as obesity, cardiovascular and metabolic diseases, as well 
as specific cancers.2,5–7,9,13,14,18,25,27
The causative mechanisms underlying these associa-
tions are largely unknown, and the absolute magnitude of 
the risks has not been well defined.5 Many of these comor-
bid conditions are directly related to the underlying severity 
of AD and inadequate disease control. On the other hand, 
most of these comorbidities affect children, while oth-
ers occur during adulthood in patients with long-standing 
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disease, supporting the systemic nature of AD, and sug-
gesting that measures taken during childhood to reduce 
disease severity could protect against its development. 
Therefore, increased surveillance, early detection, and opti-
mizing management are essential to prevent or mitigate the 
risk for these costly and burdensome comorbidities.5,9
Prevention
Due to the childhood prevalence of the disease, pre-
vention is focused on the perinatal period. It is recognized 
that prevention should start as soon as possible, target-
ing the skin barrier, immune/allergy and environmental 
aspects.23 Primary prevention approaches including dietary 
supplementation, breastfeeding, hypoallergenic milks with 
hydrolysed formulas, prebiotics and probiotics, have shown 
inconsistent results and, until now, have failed to show sig-
nificant effect on decreasing the risk of developing AD.7,47–49 
Large studies about elimination diets conclude that this 
approach is not advisable and could even impair oral tol-
erance. In fact, early exposure to peanut, egg and yogurt 
could reduce the risk of sensitization.7,50–52 As genetic and 
inflammation-driven changes of epidermal barrier function 
contribute to AD onset, the daily use of emollients from birth 
in new-borns at a high risk of developing AD could be an 
effective prevention strategy.2,7,23,25,53,54
Although influencing the genetic background is not yet 
feasible, secondary prevention strategies based on trigger 
avoidance have been implemented in practical guidelines.55 
Irritants such as air or indoor pollutants can affect patients 
with sensitive skin and lead to AD exacerbations.31 The 
spectrum of relevant allergens changes with the course 
of the disease, with food allergens inducing flares in some 
infants with moderate-to-severe AD, whereas environmen-
tal allergens such as house dust mite, pollen or animal fur 
seem to be more relevant triggers in older children and 
adults.2,56,57
Nevertheless, the avoidance of potential allergens is still 
a matter of debate. The clinical relevance of IgE specific for 
a suspected allergen can be ascertained by the atopy patch 
test or by exposure tests in a sealed chamber for aeroal-
lergens. For suspected food allergy the current guidelines 
propose the suspected food administration in a blinded 
provocation test. However, these tests remain controversial 
and avoidance recommendations should only be suggested 
when there is proven evidence of relevant allergen sensiti-
zation. Even in such cases, the impact of avoidance strate-
gies might be marginal.2,25,58
Disease management and therapeutic approaches
Management of AD must consider the individual clini-
cal variability of the disease; therefore, highly standardized 
treatment rules are not recommended.14 The aims of ther-
apy goals are reducing pruritus and establishing persistent 
disease control that is sufficient to enable patients to be fully 
functional at home, work and school. Hence, a multistep 
approach with interventions aimed at avoiding relevant trig-
gers, improving the skin barrier, normalizing the skin dysbi-
osis and reducing inflammation, is mandatory.2,7,23,25
Therapy selection is largely based on disease sever-
ity (Table 1), with adjustments based on the patients’ 
age, presence of atopy-related and unrelated comorbid-
ities, treatment response, compliance concerns and cost. 
Treatment should be paired with a formal patient and car-
egiver treatment education program in order to achieve the 
best outcomes.2,12,14,15,18,25
Microbial colonization and superinfection may cause 
disease exacerbation and require additional treatment. 
Allergen-specific immunotherapy with aeroallergens may be 
Table 1 – Treatment recommendations for adults and children with atopic dermatitis (adapted from the European guidelines for treatment 
of atopic eczema)14,15
Atopic dermatitis severity
Treatment recommendations
Children Adults
Baseline:
Basic therapy
Educational programs, emollients, bath oils, and avoidance of clinically relevant allergens
Mild:
SCORAD < 25 or transient eczema
Reactive therapy with topical 
glucocorticosteroids class IIi or depending on 
local cofactors (topical calcineurin inhibitorsi, 
antiseptics including silver, silver coated 
textiles)
Reactive therapy with topical 
glucocorticosteroids class IIi or depending on 
local cofactors (topical calcineurin inhibitorsi, 
antiseptics including silver, silver coated 
textiles)
Moderate:
SCORAD 25 – 50 or recurrent eczema
Proactive therapy with topical tacrolimusi 
or glucocorticosteroids class II or IIIii, wet 
wrap therapy, UV therapy (UVB 311 nm)iii, 
psychosomatic counselling, climate therapy
Proactive therapy with topical tacrolimusi 
or glucocorticosteroids class IIIii, wet wrap 
therapy, UV therapy (UVB 311 nm, medium 
dose UVA1), psychosomatic counselling, 
climate therapy
Severe:
SCORAD > 50 or persistent eczema
Hospitalization, systemic 
immunosuppression: cyclosporine Aii, 
methotrexateii, azathioprineii, mycophenolate 
mofetilii,iii
Hospitalization, systemic 
immunosuppression: cyclosporine Ai, 
short course of oral glucocorticosteroidsI, 
dupilumabi,iii, methotrexateii, azathioprineii, 
mycophenolate mofetilii, PUVAiii, alitretinoinii,iii
i Licensed indication; ii Off-label treatment options; iii Treatment restrictions should be taken cautiously.
Additional therapeutic options should be considered for every phase; antiseptics/ antibiotics should be added in case of superinfection; if 
therapy has insufficient effect compliance and diagnosis should be considered.
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considered in selected cases. Psychosomatic counselling is 
recommended in stress-induced exacerbations.15,19 Pruritus 
is targeted with most of the recommended therapies that 
target inflammation and skin barrier disruption, but some 
patients may need additional therapy (cannabinoid receptor 
agonist, opioid receptor antagonists, memolizumab).14,25,59
The identification of individual trigger factors is cru-
cial to the management of AD, and their avoidance allows 
longer phases of remission or total clearance of symp-
toms. Numerous environmental factors can irritate the AD 
skin and elicit eczema flares, namely mechanical irritants 
(e.g. wool, irritant fabrics and fibres), chemicals (acids, 
bleaches, solvents, surfactants in cosmetic and hygiene 
products), biological (allergens, microbes), and air pollut-
ants, like tobacco smoke, volatile organic compounds, and 
traffic exhaust. Also, adequate skin care and hygiene pro-
cedures in cleansing, bathing and dressing play a relevant 
role in AD management and should be discussed with the 
patient and included in the above-mentioned educational 
intervention.6,7,12,14,18
Basic therapy is also focused on treating disturbed bar-
rier function by hydrating and lubricating topical treatment, 
the backbone of therapy for patients with mild-to-moder-
ate AD, along with adequate cleansing/bathing practic-
es.6,12,14,18,25 When used on a daily basis, moisturizers with 
non-aqueous emollients, occlusive agents and humectants 
improve barrier function, reduce AD signs and symptoms, 
and the need for topical corticosteroids.2
Topical anti-inflammatory treatment based on corticoster-
oids and calcineurin inhibitors is indicated for flare manage-
ment and for proactive therapy for long-term control. Topical 
corticosteroids (TCSs) remain the first line treatment, reduc-
ing disease recurrence when used intermittently in patients 
with established disease.2,12,14,18,25 TCSs are grouped into 
classes according to anti-inflammatory potency, and selec-
tion of steroid should be guided by location, extent and 
acute or chronic nature of skin lesions, patients’ age, and 
disease severity. Low-potency TCSs are indicated for mild 
disease, flexural and facial skin lesions, young children and 
pregnant women.2,12,18 High potency TCSs are preferred for 
older patients, lichenified and chronic prurigo-like lesions 
and palms. Topical calcineurin inhibitors (TCIs), tacrolimus 
and pimecrolimus, approved for short-term and chronic 
intermittent use in children aged 2 and older and adults, are 
preferred in sensitive skin areas, such as face and flexural 
skin.2,12,14,18,25 TCIs inhibit cutaneous T cell activation and pro-
liferation and may also have epidermal barrier repair actions. 
Their use is limited by reduced efficacy, burning or pruritus 
commonly observed during the first week of use (especial-
ly with tacrolimus), and cost.2 Topical phosphodiesterase 
inhibitors, like crisaborole, a new topical anti-inflammatory 
class that inhibits the intracellular enzyme cAMP-specific 
3ʹ,5ʹ-cyclic phosphodiesterase 4 (PDE4), could offer another 
topical nonsteroidal option for individuals with mild-to-mod-
erate AD or in anatomically sensitive sites.2,7,14
If disease control cannot be achieved with topical meas-
ures, short-term phototherapy should be considered as 
adjuvant. UV irradiation, preferably with narrow-band ultra-
violet B (NB-UVB/UVB 311 nm) and medium-dose ultravio-
let A1 (UVA1) light, is the most effective.2,6,12,14,18,25
When topical therapies and phototherapy fail or become 
unacceptable or impractical, systemic therapy is indicat-
ed.25,60 Systemic non-biologic therapies include the non-
specific immunosuppressants cyclosporine, azathioprine, 
methotrexate and mycophenolate mofetil, which are the 
established and widely available options for severe refrac-
tory cases.2,14,15 Cyclosporine, the only systemic drug 
licensed for short-term treatment of AD (not more than 1 – 2 
years), was the most effective but its use is limited by poten-
tial toxicities, particularly nephrotoxicity.2,25 Azathioprine and 
methotrexate are effective and safe off-label treatments for 
severe AD, even in children. Mycophenolate mofetil, also 
used off-label for AD, has a more-favourable safety profile, 
but a more-limited efficacy, and is considered a third line 
option or a maintenance therapy after disease control with 
another more-effective systemic treatment. Studies showed 
azathioprine and mycophenolate mofetil have very similar 
drug survival profiles, but azathioprine was discontinued 
mainly because of adverse effects, whereas mycophenolate 
mofetil was discontinued mainly owing to ineffectiveness.2 
Although approved for AD treatment, published treatment 
guidelines suggest that systemic corticosteroids should be 
used as a last resort to manage acute flares or as a bridge 
to the use of another systemic, steroid-sparing therapy, and 
not for long-term management of AD.2,6,25,61
Targeting the Th2 pathway with dupilumab, a fully 
human monoclonal antibody against IL-4Rα that blocks both 
IL-4 and IL-13 signalling, may be a safe and effective, dis-
ease-modifying alternative. It showed significant improve-
ments in disease severity and increased the number of 
patients achieving a response, particularly when combined 
with TCSs.2,7,12,62 Dupilumab was the first biological drug 
approved by both the Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) for the treat-
ment of adults with moderate-to-severe AD and trials are 
underway to assess its safety as well as its effectiveness in 
the paediatric population.2
Several therapies are in the late stages of clinical devel-
opment for AD. Many biologics and small molecule antag-
onists are actually in phase II and phase III trials targeting 
different pathways, including Th2 immune response, JAK 
signalling and itch mediators, among others.7,15 Many JAK 
inhibitors are in development as oral therapies for moder-
ate-to-severe AD or as topical treatments for mild-to-mod-
erate AD. JAK inhibitors block a range of cytokines, growth 
factors and/or hormone receptor signalling pathways 
depending on their relative specificity.2,6,7,15 Monoclonal 
antibodies, such as mepolizumab, benralizumab and resli-
zumab, all three approved to treat asthma, have been 
developed to neutralize IL-5, which promotes eosinophil 
recruitment. Thus far, only mepolizumab has been evalu-
ated in AD with unfavourable results, which question the 
benefit of this anti-eosinophil strategy in adult patients. 
Ustekinumab, a FDA-approved therapy for psoriasis, which 
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targets the common p40 subunit of IL-12 and IL-23, failed to 
show efficacy in adults with moderate-to-severe AD.2,7
Despite these options, the treatment of moderate-to-se-
vere AD remains challenging and novel, efficacious, safe 
and targeted treatments are urgently needed. 
CONCLUSION
AD is one of the most prevalent diseases worldwide and 
is associated with a very burdensome impact on health-care 
resources and patients and caregivers’ QoL. Moreover, AD 
is associated with numerous medical and mental health 
comorbidities, with important implications for its manage-
ment and treatment. Considering there is also increasing 
evidence that AD may progress to other allergic pheno-
types, a clear need to improve disease prevention arises.
The systemic nature of the disease leads to an urgent 
need for a more systemic approach to establish safe and 
effective therapies that target its pathophysiology, which 
is more complex than previously recognized and not yet 
fully understood.
The study of AD is a fast-moving field and despite enor-
mous steps forward, a greater understanding of the dis-
ease is required. Future research in AD must now focus on 
exploring gene-environment interactions and its effect on 
pathophysiology, disease severity, and treatment outcomes.
A better definition of AD genotypes and clinical pheno-
types will improve clinical and epidemiological research, 
allowing the identification of personalized targets for better 
therapy outcomes and avoidance strategies where environ-
mental factors play a crucial role in the disease course.
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